Lindbrook Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Lindbrook Capital’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.78K	Buy	319 +105	+49%	+$918	﹤0.01%	2313
2024 Q4	$1.73K	Sell	214 -48	-18%	-$440	﹤0.01%	2348
2024 Q3	$2.69K	Buy	262 +48	+22%	+$475	﹤0.01%	2257
2024 Q2	$1.51K	Sell	214 -168	-44%	-$1.5K	﹤0.01%	2416
2024 Q1	$5.25K	Buy	382 +168	+79%	+$2K	﹤0.01%	1875
2023 Q4	$1.97K	Buy	+214	New	+$1.55K	﹤0.01%	2267
2023 Q3	–	Sell	-172	Closed	-$1.33K	–	2792
2023 Q2	$1.33K	Buy	+172	New	+$977	﹤0.01%	2309

Other funds holding ORIC

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lindbrook Capital's ORIC Position: Q1 2025 in Review

Lindbrook Capital increased its Oric Pharmaceuticals (ORIC) stake by 49% in Q1 2025, buying an estimated $918 and bringing the position to 319 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Lindbrook Capital first reported a position in ORIC in Q2 2023 and has held it in 7 quarters since. The position peaked at $5.25K in Q1 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

Lindbrook Capital held 319 shares of Oric Pharmaceuticals worth $1.78K as of Q1 2025.
Lindbrook Capital bought 105 Oric Pharmaceuticals shares in Q1 2025, an estimated $918.
Oric Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2313 holding.
Lindbrook Capital first reported a position in Oric Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Lindbrook Capital's Oric Pharmaceuticals position peaked at $5.25K in Q1 2024.
143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.